Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature
John G. Facciponte, … , George Coukos, Andrea Facciabene
John G. Facciponte, … , George Coukos, Andrea Facciabene
Published March 18, 2014
Citation Information: J Clin Invest. 2014;124(4):1497-1511. https://doi.org/10.1172/JCI67382.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 83

Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature

  • Text
  • PDF
Abstract

Tumor endothelial marker 1 (TEM1; also known as endosialin or CD248) is a protein found on tumor vasculature and in tumor stroma. Here, we tested whether TEM1 has potential as a therapeutic target for cancer immunotherapy by immunizing immunocompetent mice with Tem1 cDNA fused to the minimal domain of the C fragment of tetanus toxoid (referred to herein as Tem1-TT vaccine). Tem1-TT vaccination elicited CD8+ and/or CD4+ T cell responses against immunodominant TEM1 protein sequences. Prophylactic immunization of animals with Tem1-TT prevented or delayed tumor formation in several murine tumor models. Therapeutic vaccination of tumor-bearing mice reduced tumor vascularity, increased infiltration of CD3+ T cells into the tumor, and controlled progression of established tumors. Tem1-TT vaccination also elicited CD8+ cytotoxic T cell responses against murine tumor-specific antigens. Effective Tem1-TT vaccination did not affect angiogenesis-dependent physiological processes, including wound healing and reproduction. Based on these data and the widespread expression of TEM1 on the vasculature of different tumor types, we conclude that targeting TEM1 has therapeutic potential in cancer immunotherapy.

Authors

John G. Facciponte, Stefano Ugel, Francesco De Sanctis, Chunsheng Li, Liping Wang, Gautham Nair, Sandy Sehgal, Arjun Raj, Efthymia Matthaiou, George Coukos, Andrea Facciabene

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 Total
Citations: 1 6 1 4 6 5 4 3 5 4 8 47
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (47)

Title and authors Publication Year
Pan-cancer analysis identified CD248 as a potential target for multiple tumor types
Guo L, Liao Y, Zhang X, Guo R, Wang Z, Yang D
Frontiers in Pharmacology 2025
Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches
Lu S, Gan L, Lu T, Zhang K, Zhang J, Wu X, Han D, Xu C, Liu S, Yang F, Qin W, Wen W
Theranostics 2024
Group XIV C-type lectins: emerging targets in tumor angiogenesis.
Yee EJ, Vigil I, Sun Y, Torphy RJ, Schulick RD, Zhu Y
Angiogenesis 2024
Probiotic-derived amphiphilic exopolysaccharide self-assembling adjuvant delivery platform for enhancing immune responses
Sheng S, Zhang H, Li X, Chen J, Wang P, Liang Y, Li C, Li H, Pan N, Bao X, Liu M, Zhao L, Li X, Guan P, Wang X
Journal of nanobiotechnology 2024
Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?
Tadic S, Martínez A
Frontiers in immunology 2024
Personalized nanovaccines for treating solid cancer metastases
Feng T, Hu J, Wen J, Qian Z, Che G, Zhou Q, Zhu L
Journal of Hematology & Oncology 2024
Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas
Chen J, Sobecki M, Krzywinska E, Thierry K, Masmoudi M, Nagarajan S, Fan Z, He J, Ferapontova I, Nelius E, Seehusen F, Gotthardt D, Takeda N, Sommer L, Sexl V, Münz C, DeNardo D, Hennino A, Stockmann C
EMBO Molecular Medicine 2024
Vasculature organotropism in drug delivery
Amruta A, Iannotta D, Cheetham SW, Lammers T, Wolfram J
Advanced Drug Delivery Reviews 2023
Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production
Bayart C, Mularoni A, Hemmani N, Kerachni S, Jose J, Gouet P, Paladino J, Le Borgne M
Pharmaceuticals 2022
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Zhang Y, Brekken RA
Journal of leukocyte biology 2022
Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies
Caligola S, De Sanctis F, Canè S, Ugel S
Frontiers in Genetics 2022
Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens
Zhang SW, Wang H, Ding XH, Xiao YL, Shao ZM, You C, Gu YJ, Jiang YZ
2022
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
ZR Huinen, EJ Huijbers, JR van Beijnum, P Nowak-Sliwinska, AW Griffioen
Nature Reviews Clinical Oncology 2021
Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression
S Pierini, A Mishra, R Perales-Linares, M Uribe-Herranz, S Beghi, A Giglio, S Pustylnikov, F Costabile, S Rafail, A Amici, JG Facciponte, C Koumenis, A Facciabene
Journal for ImmunoTherapy of Cancer 2021
The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma
K Zhang, C Xu, S Liu, Y Jiang, X Zhao, S Ma, Y Li, F Yang, Y Wang, P Meng, C Shi, D Han, W Wen, W Qin
Frontiers in Oncology 2021
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1
JK Fierle, M Brioschi, M de Tiani, L Wetterwald, V Atsaves, J Abram-Saliba, TV Petrova, G Coukos, SM Dunn
Reproduction 2021
TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer
Efthymia-Iliana Matthaiou, Yi Guo, Jaleh Barar, Raphael Sandaltzopoulos, Lana E Kandalaft, Chunsheng Li, George Coukos, Yadollah Omidi
BioImpacts : BI 2021
CD248 as a bridge between angiogenesis and immunosuppression: a promising prognostic and therapeutic target for renal cell carcinoma
S Liu, C Xu, K Zhang, D Han, F Yang, Y Li, X Zhao, S Ma, H Li, S Lu, T Lu, J Zhang, W Qin, W Wen, B Yang
Annals of translational medicine 2021
Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target
Stefano Pierini, Janos L. Tanyi, Fiona Simpkins, Erin George, Mireia Uribe-Herranz, Ronny Drapkin, Robert A Burger, Mark A Morgan, Andrea Facciabene
JCI Insight 2020
Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis
CH Pai, SR Lin, CH Liu, SY Pan, H Hsu, YT Chen, CT Yen, IS Yu, HL Wu, SL Lin, SW Lin
Scientific Reports 2020
CD248 as a novel therapeutic target in pulmonary arterial hypertension
T Xu, L Shao, A Wang, R Liang, Y Lin, G Wang, Y Zhao, J Hu, S Liu
Clinical and Translational Medicine 2020
Endosialin (TEM1) as a Diagnostic, Progression, and Prognostic Serum Marker for Patients With Colorectal Cancer—A Preliminary Study
Ł Pietrzyk, P Wdowiak
Cancer control : journal of the Moffitt Cancer Center 2020
HNSCC: Tumour Antigens and Their Targeting by Immunotherapy
A von Witzleben, C Wang, S Laban, N Savelyeva, CH Ottensmeier
Cells 2020
C‐type lectin domain group 14 proteins in vascular biology, cancer and inflammation
KA Khan, JL McMurray, F Mohammed, R Bicknell
The FEBS journal 2019
A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors
T Doi, T Aramaki, H Yasui, K Muro, M Ikeda, T Okusaka, Y Inaba, K Nakai, H Ikezawa, R Nakajima
Investigational New Drugs 2019
CD248: A therapeutic target in cancer and fibrotic diseases
BA Teicher
Oncotarget 2019
Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium
Russell KL, Gorgulho CM, Allen A, Vakaki M, Wang Y, Facciabene A, Lee D, Roy P, Buchser WJ, Appleman LJ, Maranchie J, Storkus WJ, Lotze MT
Cancer journal (Sudbury, Mass.) 2019
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
KA Khan, RS Kerbel
Nature Reviews Clinical Oncology 2018
Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression
Z Tan, L Liu, MS Chiu, KW Cheung, CW Yan, Z Yu, BK Lee, W Liu, K Man, Z Chen
OncoImmunology 2018
Non-thermal plasma induces immunogenic cell death in vivo in murine CT26 colorectal tumors
AG Lin, B Xiang, DJ Merlino, TR Baybutt, J Sahu, A Fridman, AE Snook, V Miller
OncoImmunology 2018
Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice
KP Fabian, N Chi-Sabins, JL Taylor, R Fecek, A Weinstein, WJ Storkus
OncoImmunology 2017
Trial Watch: DNA-based vaccines for oncological indications
S Pierini, R Perales-Linares, M Uribe-Herranz, JG Pol, L Zitvogel, G Kroemer, A Facciabene, L Galluzzi
OncoImmunology 2017
Local Endothelial Complement Activation Reverses Endothelial Quiescence, Enabling T-cell Homing and Tumor Control during T-cell Immunotherapy
A Facciabene, FD Sanctis, S Pierini, ES Reis, K Balint, J Facciponte, J Rueter, M Kagabu, P Magotti, E Lanitis, RA DeAngelis, RJ Buckanovich, WC Song, JD Lambris, G Coukos
OncoImmunology 2017
Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine
SC Wagner, TE Ichim, V Bogin, WP Min, F Silva, AN Patel, S Kesari
Oncotarget 2017
Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.
Fabian KL, Storkus WJ
Advances in experimental medicine and biology 2017
Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates
Ł Pietrzyk
Disease Markers 2016
Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors
Y Zhang, HC Ertl
Oncotarget 2016
Safety of targeting tumor endothelial cell antigens
SC Wagner, NH Riordan, TE Ichim, J Szymanski, H Ma, JA Perez, J Lopez, JJ Plata-Munoz, F Silva, AN Patel, S Kesari
Journal of Translational Medicine 2016
Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies
DJ OShannessy, H Dai, M Mitchell, S Huntsman, S Brantley, D Fenstermacher, DR Reed
Sarcoma 2016
Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage
C Mogler, M Wieland, C Konig, J Hu, A Runge, C Korn, E Besemfelder, K Breitkopf-Heinlein, D Komljenovic, S Dooley, P Schirmacher, T Longerich, HG Augustin
EMBO Molecular Medicine 2015
Targeting the tumor vasculature to enhance T cell activity
E Lanitis, M Irving, G Coukos
Current Opinion in Immunology 2015
Targeting tumor vasculature: expanding the potential of DNA cancer vaccines
S Ugel, JG Facciponte, FD Sanctis, A Facciabene
Cancer Immunology, Immunotherapy 2015
Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™
TE Ichim, S Li, H Ma, YV Yurova, JS Szymanski, AN Patel, S Kesari, WP Min, SC Wagner
Journal of Translational Medicine 2015
Rheumatoid arthritis: The two faces of Rsk2 in hyperplastic disease
J Falconer, CD Buckley
Nature Reviews Rheumatology 2015
Trial watch: Naked and vectored DNA-based anticancer vaccines
N Bloy, A Buqué, F Aranda, F Castoldi, A Eggermont, I Cremer, C Sautès-Fridman, J Fucikova, J Galon, R Spisek, E Tartour, L Zitvogel, G Kroemer, L Galluzzi
OncoImmunology 2015
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma
M Mazzocco, M Martini, A Rosato, E Stefani, A Matucci, SD Santa, FD Sanctis, S Ugel, S Sandri, G Ferrarini, T Cestari, S Ferrari, P Zanovello, V Bronte, S Sartoris
Immunology 2015
Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?
SC Wagner, TE Ichim, H Ma, J Szymanski, JA Perez, J Lopez, V Bogin, AN Patel, FM Marincola, S Kesari
Journal of Translational Medicine 2015

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 8 news outlets
Blogged by 3
Posted by 5 X users
Referenced in 2 patents
Mentioned by 1 weibo users
83 readers on Mendeley
See more details